Netflix Meets Earnings Expectations and Continues to Grow Subscription Base
Netflix reported earnings after the bell and hit on expectations. The company reported EPS of $0.41 and revenue of $3.286 billion. The streaming service did add far more customers than expected during the holiday season. Netflix gained 8.3 million subscribers globally, making Q4 a particularly strong quarter.
After the strong investor relations report, shares jumped more than 8% after hours. For the first time, Netflix's market capitalization passed $100 billion.
According to Daniel Ives, the Chief Strategy Officer and Head of Technology Research at GBH Insights, the media world is Netflix's oyster. The streaming company's biggest competition at this point is Hulu. However, Ives feels strongly about the potential future growth for Netflix heading further into 2018.
Netflix made other announcements during their earnings report. The company plans to raise capital in the high yield market. They also intend to grow their technology and development investments to over $1.3 billion. Netflix will spend between $1.7 and $8 billion on content in 2018.
Seth Schachner, Managing Director at Strat Americas, on Hollywood's latest blockbusters utilizing content creation. Plus, the future of YouTube and TikTok.
Ashley Gold, Axios' Tech/Policy reporter, discusses what the future of Google and search engines will look like after the tech giant faces an antitrust trial.
A labor rights group has alleged that Starbucks sourced coffee from a major Brazilian cooperative whose member farms were cited for keeping workers in slave-like conditions.
X, the social media platform owned by Trump adviser Elon Musk, is challenging the constitutionality of a Minnesota ban on using deepfakes to influence elections and harm candidates.
Seth Goldstein, Equity Strategist at Morningstar, breaks down Tesla's earnings report, talks Musk's future with the company and how stocks have responded.
Senior Health Correspondent for TIME, Alice Park, gives us a deeper look into how Eli Lilly's new pill orforglipron may change the healthcare industry.
